Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: InvestorLady who wrote (712)	5/4/1998 6:57:00 PM
From: Gabe Fernandez	Read Replies (1) \| Respond to of 1491

thanks for the explanation- any idea of why a move of .50 in a 2.50 stock,that is a substantial increase. Also would like to hear from an eye surgeon Do they use antiinflamatory medication in all eye cases and if so i get the impression that PARS product is superior to others.. To this i will add as a Neurosurgeon that I managed severe head injuries for 32 years,an improvment of 50% in the mortality rate on head injuries of a Glasgow Coma Scale (GCS) between 4 and 8 is outstanding if findings can be confirmed and reproduced. To this i do not mentioned Tamoxifen variant without estrogenic activity and Uterine Cancer problems. If the last 2 -are beneficial the sky is the limit.